Nefazodone relief of alprazolam interdose dysphoria: a potential therapeutic benefit of 3A3/4 inhibition.
Ketter
T A
TA
Callahan
A M
AM
Post
R
R
D000525:Alprazolam / Q000009:adverse effects* / Q000627:therapeutic use; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D001007:Anxiety / Q000139:chemically induced / Q000188:drug therapy; D065607:Cytochrome P-450 Enzyme Inhibitors; D003863:Depression / Q000139:chemically induced* / Q000188:drug therapy; D003866:Depressive Disorder / Q000188:drug therapy; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D010879:Piperazines; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*
D018687:Antidepressive Agents, Second-Generation; D065607:Cytochrome P-450 Enzyme Inhibitors; D010879:Piperazines; D014230:Triazoles; C051752:nefazodone; D000525:Alprazolam